NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”). FULC, and certain officers. The class action, filed in the U.S. District Court for the District of New Jersey and filed number 23-cv-02360, is directed on behalf of a class consisting of all individuals and entities other than defendants, the Fulcrum Bought or otherwise acquired securities on March 3, 2022 and March 8, 2023, both dates inclusive (the “Collection Period”), for the purpose of seeking damages caused by the Defendants’ violations of the federal securities laws and remedy under Sections 10(b) and 20(a). of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated therein against the Company and certain of its top officials.

If you are a shareholder who purchased or otherwise acquired Fulcrum securities during the class action period, you have until June 27, 2023 to petition the court to appoint lead plaintiff in the class action. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, direct line. 7980. Anyone inquiring by email will be asked to provide their postal address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Fulcrum is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. One of the company’s lead product candidates is FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell anemia and other hemoglobinopathies. During 2022, Fulcrum submitted preclinical data to the U.S. Food and Drug Administration (“FDA”) related to the Company’s intention to…